Locate providers:   

ASPS Joins Forces with FDA In Response to Potential Rare Cancer Risk


The ASPS is working in conjunction with the FDA to build a registry to track breast implant patients and information to better determine any risks.

fda breast implants
Model Photo

In response to a release from the FDA stating that there is a possible link between breast augmentation using implants and a very rare form of cancer, the American Society of Plastic Surgeons (ASPS) has issued a statement and says they are working closely with the FDA. The ASPS is focusing efforts on establishing a national registry for breast implants in response to this finding.

All groups involved have made it clear that more testing and data are needed to determine if the risk is real. Further, the cancer in question is a very rare form of lymphoma - Anaplastic Large Cell Lymphoma (ALCL). This cancer is only found in a very small handful of cases. Though numbers stated vary, likely under 60 patients with breast implants have developed this cancer worldwide, and there are an estimated 10 million implants around the world.

The American Academy of Cosmetic Surgery (AACS) has also issued a statement regarding the FDA's findings.

The FDA, the AACS and the ASPS all advise that women with implants not panic about this news and that they instead continue with regular breast exams both at home and with their doctors. They do say that as always, women should monitor their breasts for any swelling or discomfort and contact their physicians with questions.